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Introduction
Nucleic acid sequences containing repetitive guanine (G)-rich
tracts can form G-quadruplex higher-order structures (G4), in
which guanine bases form stacked planar G-quartets stabilised
by Hoogsteen hydrogen bonding and cation coordination.[1]
Bioinformatics analyses of the human genome have revealed
an elevated frequency in the occurrence of these sequences,
notably in telomeres and promoter regions of genes such as
the oncogenes c-Myc, c-Kit, and K-Ras,[2] thus suggesting that
G4s may naturally act as regulatory elements, particularly in
cell proliferation processes.[3] Recently, the 27-nucleotide se-
quence located 77 nucleotides upstream of the transcription
start site of Hsp90, a gene that encodes a protein involved in
the regulation of cell proliferation and a validated target for
cancer therapy,[4] was also shown to form stable quadruplex
DNA structures.[5] Down-regulation of transcription by small
molecules that are able to induce and stabilise DNA G4 struc-
tures has been reported for oncogenes c-Myc,[6] c-Kit,[7] KRas,[8]
and Hsp90,[9] reinforcing the concept that G4s are promising
targets for the design of new compounds (G4 ligands) with po-
tentially high cancer cell selectivity and lower toxicity than
standard DNA-targeting anticancer drugs.[3a] Moreover, target-
ing G-quadruplexes in promoter oncogenes has several advan-
tages over targeting expressed proteins, including the de-
creased likelihood of point mutations and resistance. However,
from a drug-discovery perspective, we are still taking the first
steps, as there is currently restricted diversity in the available
G4 ligands, and these have low affinity and selectivity for G4
relative to protein inhibitors.[3a] The large planar and aromatic
surface of a terminal G-quartet is a common G4 chemical fea-
ture that has led to the development of mainly three G4
ligand families: the macrocyclic family, of which the porphyrin
derivative TMPyP4 and telomestatin are well-known examples;
the polyaromatic fused family, which includes acridines, anthra-
G-quadruplex (G4) DNA structures in telomeres and oncogenic
promoter regions are potential targets for cancer therapy, and
G4 ligands have been shown to modulate telomerase activity
and oncogene transcription. Herein we report the synthesis
and G4 thermal stabilisation effects, determined by FRET melt-
ing assays, of 20 indolo[3,2-b]quinolines mono-, di-, and trisub-
stituted with basic side chains. Molecular modelling studies
were also performed in an attempt to rationalise the ligands’
binding poses with G4. Overall, the results suggest that ligand
binding and G4 DNA thermal stabilisation increase with an N5-
methyl or a 7-carboxylate group and propylamine side chains,
whereas selectivity between G4 and duplex DNA appears to
be modulated by the number and relative position of basic
side chains. From all the indoloquinoline derivatives studied,
the novel trisubstituted compounds 3d and 4d, bearing a 7-
(aminoalkyl)carboxylate side chain, stand out as the most
promising compounds; they show high G4 thermal stabilisa-
tion (DTm values between 17 and 8 8C) with an inter-G4 DTm
trend of Hsp90A>KRas21RF21T>c-Kit2, 10-fold selectivity
for G4 over duplex DNA, and 100-fold selectivity for the
HCT116 cancer cell line (IC50 and IC90: <10 mm) over primary
rat hepatocytes. Compounds 3d and 4d also decreased pro-
tein expression levels of Hsp90 and KRas in HCT116 cancer
cells.
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quinones, and indoloquinoline derivatives; and the family of
aromatic non-fused systems such as 1,4-triazole derivatives.[10]
Many of these G-quadruplex ligands are selective for G4 struc-
tures over duplex DNA, but the design of inter-G4 selective li-
gands remains challenging. However, in view of the high
number of putative G4-forming sequences revealed by the
analysis of the human genome, this issue needs to be ad-
dressed in order to avoid secondary and undesirable effects in
any therapeutic application of G4 targeting. Monomolecular
G4s can adopt a wide diversity of topologies and have various
loops, grooves, and capping structures as a consequence of
differences in their primary DNA sequences. Adenines, thy-
mines, and phosphate groups present in loops, grooves, and
capping structures of G4 provide distinct patterns of hydrogen
bonding, hydrophobic p surfaces, and negative charges that
can be selectively targeted.[11] Crystallographic and NMR stud-
ies of G4–ligand complexes have shown that fused polyaro-
matic ligands such as acridines and indoloquinolines bind to
G4s through p–p stacking with guanines of terminal G-quar-
tets, while side chains target the grooves and loops of the G4,
contributing both to enhanced binding and selectivity be-
tween G4s.[12]
Indoloquinolines are tetracyclic aromatic alkaloids with high
potential to be developed into anticancer drugs, but have
been insufficiently exploited.[13a] Derivatives of natural indolo-
[3,2-b]quinolines 1 (quindoline) and 2a (cryptolepine) were
previously shown to be good G4 ligands, telomerase inhibitors,
oncogene (c-Myc) transcription inhibitors, and are able to
induce cell-growth arrest (Figure 1).[14] Moreover, the drug-like
analogue NSC748393 (2b) showed good in vitro and in vivo
anticancer profiles, as well as strong binding affinity to a telo-
meric G-quadruplex.[15] However, as for most G-quadruplex li-
gands known to date, C11-substituted or N10,C11-disubstituted
indolo[3,2-b]quinolines are poorly selective G4 ligands.[14b,15]
Nevertheless, the asymmetric shape of the indolo[3,2-b]quino-
line aromatic core and the substantial derivatisation potential
offered by this structure suggest that it is a very appropriate
scaffold for exploitation to obtain efficient and selective G4 li-
gands.
Embracing the challenge of expanding the chemical toolbox
of effective G4 ligands for cancer therapy, herein we describe
the design, synthesis, and G4 thermal stabilisation effects of
a set of mono-, di-, and trisubstituted indolo[3,2-b]quinolines
against three different DNA sequences—F21T human telomeric
quadruplex (F21T), c-Kit2, and Hsp90A quadruplexes—using
a high-throughput fluorescence resonance energy transfer
(FRET) melting assay. Molecular modelling was then used to ra-
tionalise the binding to telomeric quadruplexes, and the anti-
proliferative activity of the most effective and selective ligands
were evaluated in cancer and normal cells.
Results and Discussion
Design of target compounds
Previous studies have shown that thermal stabilisation of telo-
meric or c-Myc G4 by quindoline (1) derivatives increases with
increasing basicity of the quinoline nitrogen (N5) atom, for ex-
ample, when an electron-donating group (NH) is present at
C11.[14b] These results have been interpreted as indicating that
a positive charge near the aromatic core, due to protonation
of N5 at physiological pH, is an important feature to improve
binding to external G-quartets of G4 DNA structures.[14a,b]
Methylation of N5, leading to a stable positive charge, further
increased binding affinity and thermal stability of telomeric G4,
an effect that was ascribed to increased p–p stacking interac-
tions, due to a decrease in electron density in the aromatic
core.[14c] As reported for other G4 ligands, the basicity of the
quindoline side chains is also important for G4 binding,[14c] but
other chemical features of basic side chains remain unexploit-
ed. In this context, we first decided to expand the chemical di-
versity of the basic side chain at C11 and to evaluate the effect
of N5-methyl quindoline derivatives 2c–m, containing various
alkyl side chain lengths, terminal amine groups (primary, sec-
ondary, or tertiary), and different aryl side chains on G4 thermal
stabilisation.
It has been reported that appending two basic side chains
to C2 and C7 or N10 and C11 of the quindoline core increases
binding to telomeric[16] or c-Myc G4 structures.[14b] Because no
other positions of the asymmetrical quindoline nucleus have
been exploited to modulate G4 binding, we next designed
new indolo[3,2-b]quinolines, 3 and 4, with two and three basic
side chains, to evaluate the effect of various alkylamine substi-
tution patterns and of substituents at positions 3 and 7 on in-
teractions with different G4 structures.
Chemistry
Indolo[3,2-b]quinolines 2–4 were synthesised via quindolones
8 (indolo[3,2-b]quinolin-11-ones), according to the route illus-
trated in Scheme 1 and based on a procedure developed by
Gçrlitzer and Weber and adapted by Bierer.[13] In the first step
anthranilic acids 5 were allowed to react with bromoacetyl
bromide to afford compounds 6, which were then converted
into the corresponding 2-(2-(phenylamino)acetyl)benzoic acids
7 by reaction with the appropriate aniline. Acid-promoted bi-
Figure 1. Quindoline (1), cryptolepine (2a), C11 derivatives 2b–m, and quin-
doline derivatives 3 and 4 screened against a small panel of G-quadruplexes.
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cyclisation of 7a–c with polyphosphoric acid (PPA) afforded
the corresponding quindolones 8a–c. However, PPA-promoted
cyclisation of 7d did not afford the corresponding quindolone
(R1=H, R2=NO2), but another unexpected compound. The
1H NMR spectra and 1H–1H COSY data showed a total of eight
protons, instead of seven protons, and two inter-correlated
sets of doublets integrating for two protons each at 6.56 and
7.52 ppm, as in 7d for the 4-nitroaniline ring. The total assign-
ment of the 1H and 13C NMR chemical shifts by analysis of
2D HMQC and HMBC allowed the identification of 2-hydroxy-3-
((4-nitrophenyl)amino)quinolin-4(1H)-one (7 id) as the product
of PPA-catalysed cyclisation of 7d. This observation led us to
propose the two-step mechanism depicted in Scheme 2. In the
case of 7d, bearing a para-nitro group in the aniline moiety,
the indoloquinoline cyclisation reaction stopped after the clo-
sure of the six-membered ring, possibly due to the strong elec-
tron-withdrawing effect of the nitro substituent which preclud-
ed closure of the five-membered ring and formation of the
final quindolone.
In addition, acid-promoted bicyclisation of 7e, with a trifluor-
omethyl substituent, gave quindolone 8c, with a carboxylic
acid group, as a bicyclisation product of 7c. Compound 8c
was fully characterised by NMR spectroscopy, which revealed
two carbonyl carbons in the 13C spectra at 167.92 and
168.18 ppm. The carbon at 168.18 ppm showed a 1H–13C
HMBC correlation with the singlet resonating at 8.99 ppm as-
signed to the proton at position 6 of the aromatic nucleus.
Analysis of the 2D NMR spectra allowed assignment of the re-
maining carbonyl signal to C11 of the aromatic nucleus. Fur-
thermore, 19F NMR data of the product from 7e bicyclisation
did not reveal any signal resonating in the spectrum, in con-
trast to what was observed for the starting material 7e, which
showed a singlet at 59.09 ppm. Mass spectrometric analysis
also corroborates the presence of a carboxylic acid instead of
a trifluoromethyl substituent. In this particular system, the elec-
tronic effect of the indole nitrogen atom promoted an SN1-
type cleavage of the CF bond in the trifluoromethyl group, as
described for 3-(trifluoromethyl)-1H-indoles, followed by hy-
drolysis of the difluoromethylene intermediate.[17]
Cryptolepine (2a) and derivatives 2c–m were obtained from
8a after 11-chlorination with phosphorus oxychloride. Hydro-
genation and N5-methylation with methyl trifluoromethanesul-
fonate gave 1 and N5-methylation of the 11-chloro intermedi-
ate, followed by nucleophilic substitution with the required al-
kyldiamine to yield 2c–m. All cryptolepine derivatives were
fully characterised by NMR, and in all cases, purities were
95%, as described elsewhere.[18] Quindoline derivatives 3 and
4 were obtained by reaction of 8 with the appropriate chlor-
oalkylamine in the presence of a base, as described in a syn-
thetic procedure recently reported by our group (Scheme 3).[19]
In the case of the intermediate quindolone 8c, the same syn-
thetic procedure afforded the trialkylated derivatives 3d and
4d. The positions of N-alkylamine side chains in compounds
3a–d and 4a–d were assigned on the basis of 1H–13C correla-
tions between CH2 protons of the side chain and quaternary
carbon atoms of the quindoline aromatic structure, observed
in HMBC spectra and confirmed by NOE experiments. For ex-
ample, 1H and 13C spectra of derivative 4d displayed signals
Scheme 1. Synthesis of the indolo[3,2-b]quinoline nucleus. Reagents and con-
ditions : a) bromoacetyl bromide, DMF/1,4-dioxane (1:1), RT, overnight; b) ap-
propriate aniline; c) PPA, 130 8C, 2 h.
Scheme 2. Acid-promoted cyclisation mechanism of 7 to afford quindolones
8.
Scheme 3. Synthesis of indolo[3,2-b]quinoline derivatives 3 and 4. Reagents
and conditions : a) chloroalkylamine, K2CO3, dry acetone, reflux, overnight.
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corresponding to the introduction of three side chains in the
quindoline nucleus. The disappearance of the carbonyl carbon
signal resonating at 167.92 ppm in 8c (C11), replaced by a typi-
cal phenoxy carbon signal at 145.15 ppm and an additional
ether carbon (74.79 ppm), correlating in the HMQC with a 1H
triplet (4.31 ppm), indicated the presence of an alkoxy chain at
C11.
This triplet revealed a NOE correlation with a triplet at
4.73 ppm, which correlated in HMBC with C9a and C10a
(147.36 and 125.30 ppm, respectively) and in the 1H–1H COSY
spectrum with two methylene protons, corroborating the in-
troduction of a second side chain at position N10. The third
side chain was characterised in 1H NMR data by two triplets, in-
tegrating to two protons each, at 2.96 and 4.49 ppm, one
quartet at 2.70 ppm integrating for four protons, and one trip-
let at 1.12 ppm integrating for six protons. The triplet at
4.49 ppm correlated in the HMBC spectrum with the carbonyl
carbon (166.84 ppm), which in turn correlated with the singlet
at 9.24 ppm, assigned to H6, thus confirming the introduction
of the third side chain in the carboxylic acid moiety of 8c and
formation of the 2-(diethylamino)ethyl-11-[2-(diethylamino)-
ethoxy]-10-[2-(diethylamino)ethyl]-10H-indolo[3,2-b]quinolone-
7-carboxylate (4d) (Supporting Information).
G-quadruplex stabilisation
The ability of the indolo[3,2-b]quinolines 2–4 to bind and sta-
bilise G4 structures and a self-complementary hairpin DNA (T-
loop) was evaluated by FRET melting assays with ligand con-
centrations ranging from 0.1 to 5 mm. The FRET melting data,
given as changes in melting temperature (DTm) and obtained
with fluorescently labelled DNA G4 sequences (0.2 mm) of F21T
human telomeric DNA[20] and of oncogene promoter sequen-
ces c-Kit2[7a] and Hsp90A,[5] as well as with T-loop in potassium
ion buffer, are summarised in Tables 1 and 2. The results show
that the indolo[3,2-b]quinolines 2–4 produce a wide range of
G4 stabilisation effects, and, for all compounds, these effects
are concentration dependent, with much higher stabilisation
effects at 5 mm than at 1 mm, as shown in Figure 2 for 2e and
4d (see Supporting Information for the remaining com-
pounds).
Cryptolepine derivatives 2c–m showed DTm values ranging
from 2 to 25 8C at 2 mm for Hsp90A, F21T, and c-Kit2, in most
cases increased relative to parent compound 2a and are simi-
lar to those reported elsewhere for human telomeric G4.[14c, 15]
Compounds with aliphatic amine side chains (2c–i), which at
physiological pH are expected to be double protonated,[21]
showed higher stabilisation effects with G4. From those, 2e–g
with propyl side chains showed the highest degree of stabilisa-
tion, with DTm values ranging from 17 to 25 8C. These results
show for the first time in the case of C11-monosubstituted
indolo[3,2-b]quinolines, that there is an optimal NH-alkylamine
side chain length for G4 stabilisation, in accordance with previ-
ous observations for di- and trisubstituted acridines[22] and
naphthalene diimides,[23] that propylamine side chains are su-
perior to ethyl or butylamine. Changing the distal part of the
propylamine side chain from a primary to a secondary or terti-
ary amine (2e–g) does not significantly change the complex
stabilisation, despite the differences between pKa values ob-
served for those amine groups (pKa values ranging from 8.7 to
~12).[21] However, compound 2d, which contains a weak termi-
nal amine with a pKa value of 7.7,
[21] or compound 2 l with an
N-(2-hydroxybenzyl)piperidine side chain in which the basicity
of the tertiary amine is expected to be lower due to hydrogen
bond interactions with the 2-hydroxy group of benzyl, and
compounds 2 j,k,m that have no basic side chains, showed
lower G4 stabilisation (DTm: 2–15 8C). This confirms that elec-
trostatic or hydrogen bond interactions between the ligand
protonated side chain and the G4 structures are important fac-
tors for complex stabilisation, as suggested by molecular mod-
elling studies,[14c] although this could not be confirmed by
NMR analysis of a c-Myc promoter G4 and the 11-((2-dimethyla-
mino)ethylamino)quindoline complex.[12c] The melting data for
T-loop with compounds 2 showed, in most cases, a similar out-
line in comparison with G4 data (Table 1), and no significant
selectivity for G4 structures would be expected.
The indolo[3,2-b]quinolines with two (3a–c, 4a–c) and three
(3d, 4d) alkylamine side chains, which are expected to be di-
and triprotonated at physiological pH, respectively, were found
Figure 2. Concentration-dependent FRET melting profile of G4 structures
and T-loop DNA complexed with compounds a) 2e and b) 4d.
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to be less effective stabilisers of G4 structures (DTm<17 8C)
than monosubstituted N5-methylindoloquinolines 2c–i. This
observation suggests that the positive charge at the aromatic
moiety, which can be ascribed to decreased electron density
and consequently stronger interactions with the electron-rich
p system of a G-quartet, is more important for G4 stabilisation
than positive charges at side chain termini, as in the case of 3
and 4. This is consistent with the type of interactions observed
between 11-((2-dimethylamino)ethylamino)quindoline and the
c-Myc G4 complex studied by NMR.[12c] These studies showed
that the principal forces stabilising the complex are p–p stack-
ing between the aromatic indoloquinoline ring of the ligand
and two guanines of the terminal G-quartet, whereas no par-
ticular interactions were observed between the side chain and
the G4 structure, although this could be due to the short side
chain length of the ligand.
Generally, N5,N10-disubstituted indolo[3,2-b]quinolines 3a–
c showed greater G4 stabilisation, and in particular 3b with
a propylamine side chain (DTm between 12 and 7 8C), than the
counterparts 4a–c (DTm of 4b between 5 and 3 8C), with both
side chains close to each other (at N10 and C11) and directed
to the same side of the indolo[3,2-b]quinoline aromatic core.
Boddupally et al.[14b] recently reported that the introduction of
a second alkylamine chain at N10 of an 11-piperazinylquindo-
line increases the thermal stability of a c-Myc G4 complex, al-
though subsequent competition dialysis experiments showed
that monosubstituted 11-piperazinylquindoline has higher
binding affinity for G4 structures than the corresponding
N10,C11-disubstituted compound. Remarkably, competition di-
alysis experiments also showed that despite the lower binding
affinity for G4 structures, disubstituted quindolines bind more
selectively to different G4 than monosubstituted com-
pounds,[14b] a pattern also observed in this study. N5,N10-disub-
stituted indoloquinolines 3a–b show a G4 thermal stability
trend effect of Hsp90A>F21T> c-Kit2. Also, DTm values for T-
loop suggest a weak binding affinity for duplex DNA struc-
tures. Finally, to our surprise, the introduction of an electron-
withdrawing chlorine atom at the 3-position of the indolo[3,2-
b]quinoline aromatic core seems to decrease the G4 binding
capacity of the N5,N10-disubstituted compound, as 3c has
a lower DTm (5 8C for Hsp90A and 2 8C for F21T) than the ethyl
side chain analogue 3a (DTm values of 8 8C for Hsp90A and 4 8C
for F21T).
The introduction of an alkylamine carboxylate side chain at
the 7-position of the indolo[3,2-b]quinoline aromatic core, as in
the case of trisubstituted compounds 3d and 4d, clearly im-
proves binding to G4 DNA structures (DTm between 16 and
7 8C for both compounds), maintaining the inter-G4 thermal
stability trend effect Hsp90A>F21T>c-Kit2>T-loop (see Fig-
ure 2b for compound 4d) and also suggesting weak binding
affinity for duplex DNA structures. However, in the case of tri-
substituted indoloquinolines 3d (C7,N5,N10-substituted) and
4d (C7,N10,O11-substituted) the relative positions of the three
side chains has no effect on G4 stabilisation, as observed for
disubstituted indoloquinolines 3a–c (N5,N10-substituted) and
4a–c (N10,O11-substituted). Overall, the results suggest that
the electron-withdrawing carboxylate group at the 7-position
can increase p–p stacking interactions between the aromatic
indoloquinoline ring and the terminal G-quartet of G4s by de-
creasing the electron density of the former.
The trisubstituted derivatives 3d and 4d were also evaluat-
ed for their stabilisation effects on the G4-forming promoter
sequence of KRas[24] (Table 2). Compound 4d is as good a stabil-
iser of the G4 sequence KRas21R (DTm=13 8C) as of F21T. The
G4 stabilising effect of compound 4d was further evaluated
with c-Kit1,[7a] HIF-1a,[25] and Hsp90C (comprising the full G4 se-
quence in the Hsp90 promoter region)[5] (Figure 2). The results
showed a similar stabilisation of the oncogenic c-Kit1 G4
(DTm=7 8C at 2 mm ligand concentration), compared with c-
Kit2 and lower stabilisation of HIF-1a (DTm=3 8C) relative to
the remaining G4 structures. Despite 4d being a good stabilis-
er of Hsp90A G4 (DTm=17 8C), no significant stabilisation of
the oncogene promoter Hsp90 full sequence G4 was observed
(DTm=3 8C). These results further suggest the capacity of tri-
substituted indolo[3,2-b]quinolines to discriminate between G4
structures.
To access the selectivity of these ligands for G4 over duplex
DNA, suggested by DTm data, competitive FRET experiment
with F21T G4 and 4d was performed in the presence of a non-
fluorescent duplex DNA competitor (26ds)[26] (Figure 3). The re-
sults indicate that stabilisation of the telomeric G4 is only af-
fected in the presence of 50-fold excess of competitor 26ds,
showing that this compound is at least 10-fold more selective
for G4 than for duplex DNA.
Table 1. Melting temperatures of DNA structures stabilised by 2a–m at
2 mm.
Compd R1 DTm [8C]
[a]
Hsp90A[b] F21T[c] c-Kit2[d] T-loop[e]
2a H 10.1 7.0 5.0 3.2
2c 18.7 13.9 12.3 7.8
2d 12.1 11.4 8.1 9.3
2e 19.9 21.3 18.6 18.9
2 f 25.0 21.9 16.8 19.3
2g 23.8 21.3 17.0 19.9
2h 22.2 18.4 13.5 13.9
2i 18.0 15.8 11.4 14.5
2j 9.6 5.5 2.78 4.7
2k 9.8 5.9 3.5 3.5
2l 15.6 10.9 7.5 6.4
2m 6.8 3.0 2.1 1.5
[a] DTm0.3. [b] Tm=59.0 8C. [c] Tm=57.9 8C. [d] Tm=58.4 8C. [e] Tm=
53.2 8C.
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Molecular modelling studies
To understand the structural basis of G4 binding in this class of
ligands, molecular modelling of several compounds with avail-
able G-quadruplexes structures was performed. Based on FRET
melting data, which showed the highest stabilisation of G4
structures in the promoter of Hsp90A and human telomeres by
indolo[3,2-b]quinolines, and in the absence of Hsp90A G4 struc-
ture, several intramolecular G4 structures with different topolo-
gies were selected.[27]
In physiologically relevant potassium ion concentrations,
human telomeric DNA can adopt antiparallel, hybrid, or parallel
arrangements.[28] However, due to water depletion, the antipar-
allel and hybrid arrangements under crowded conditions are
converted into propeller-type parallel strands.[29] To generate
our models, four experimentally determined structures of G4
human telomere were chosen as starting points: 1) the 22-mer
unimolecular propeller-like parallel with three stacked G-quar-
tets (PDB ID 1KF1);[30] 2) the 22-mer unimolecular antiparallel
basket-type with three stacked G-quartets, which are connect-
ed by two lateral loops and a central diagonal loop (PDB ID
143D);[31] and 3) and 4) the 26-mer unimolecular hybrid-type1
and -type2 mixed parallel/antiparallel-G-stranded G-quadru-
plexes (PDB IDs 2HY9 and 2JPZ, respectively).[32]
To achieve the 21-mer common sequence 5’-GGG TTA GGG
TTA GGG TTA GGG-3’ in all topologies, in PDB 1KF1 and 143D,
the nucleotide 5’-A was removed, nucleotides 5’-AAA and AA-
3’ were removed in PDB 2HY9, while nucleotides 5’-TTA and
TT-3’ were removed in PDB 2JPZ. The presence of the K+ ions
are very important for the stability of G4; the absence of coor-
dination cations modifies the structures, causing evident defor-
mation or disruption.[33] Therefore, K+ ions were added be-
tween the guanine stacks to the first single G4 of the ensem-
bles of NMR structures (PDB IDs 143D, 2HY9, and 2JPZ) and
used as starting points. Refinement of the G4 structures was
performed by molecular dynamics (MD) simulations in water
with the appropriate number of counterions for neutrality of
the system and sampling the NpT ensemble (p=1 bar, T=
298 K) for 10 ns. During the complete course of MD simulation
the integrity of the G4 persisted, with the RMSD of all atoms
of the structure stabilising around 1.9, 2.5, 2.6, and 2.5  for
Table 2. DTm values of DNA structures stabilised by compounds 3 and 4 at 2 mm and DG values of the optimised propeller-like parallel (1KF1), antiparallel
basket-type (143D), hybrid-type1 (2HY9), and hybrid-type2 (2JPZ) G4 structures with compounds 3 and 4.
Compd R1 R2 R3 DTm [8C]
[a] DG [kcalmol1]
Hsp90A[b] F21T[c] c-Kit2[d] T-loop[e] KRas21R[f] 1KF1 143D 2HY9 2JPZ
3a H H 7.6 3.8 2.3 0.5 ND 42.7 45.4 65.1 67.6
3b H H 11.8 7.2 7.5 3.8 ND 43.9 40.6 71.6 67.9
3c Cl CH3 5.0 1.7 1.4 0.5 ND 43.3 35.7 67.6 68.7
3d H 15.9 10.6 8.7 2.2 7.4 44.7 38.1 72.6 83.6
4a H H 3.2 1.2 1.1 1.8 ND 40.5 36.0 53.8 63.9
4b H H 5.2 2.5 2.4 2.2 ND 42.5 43.0 68.5 64.0
4c Cl CH3 3.2 1.4 0.9 0.3 ND 40.4 34.2 60.2 62.2
4d[g] H 16.7 12.0 7.4 2.9 12.9 50.0 40.2 73.5 77.6
[a] DTm0.3. [b] Tm=59.0 8C. [c] Tm=57.9 8C. [d] Tm=58.4 8C. [e] Tm=53.2 8C. [f] Tm=51.5 8C; ND: not determined. [g] Also evaluated with: c-Kit1 (Tm=
60.2 8C), DTm=7.10.3 8C; Hsp90C (Tm=78.5 8C), DTm=2.80.1 8C; HIF-1a (Tm=79.5 8C), DTm=2.50.2 8C.
Figure 3. FRET melting competition assay data for the F21T–4d complex in
the absence (0 mm) and presence of increasing concentrations of duplex
(26ds) DNA competitor; the concentration of F21T was 0.2 mm.
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parallel, antiparallel, hybrid-type1, and -type2, respectively
(Supporting Information). The stacked G-quartets are very rigid
and are the most stable segment of the structure due to
strong hydrogen bonds and stacking interactions. However,
without impact on the structure of the central G-tetrad core,
the residue’s root-mean-square fluctuation (RMSF) showed that
loop nucleotides exhibited relatively larger flexibility, (Support-
ing Information), as recently described by Haider and co-work-
ers for the human propeller telomeric DNA quadruplex.[34] To
evaluate indolo[3,2-b]quinoline complex formation with the
optimised structures, several docking studies were performed
using the MD-optimised G4 structures with different topolo-
gies as starting conformations. The efficiency of the docking
methodology was validated with the crystal structure of the
human telomeric bimolecular parallel-stranded G4, co-crystal-
lised with the acridine BRACO-19 (PDB ID 3CE5),[12b] using rigid-
and induced-fit docking protocols and several refinement scor-
ing functions included in MOE v.2012.10.[35] The final docking
pose obtained with rigid docking protocol and alpha HB scor-
ing function was in good agreement with the crystallographic
pose in the 3’ end of structure, showing an RMSD of 1.8  for
all heavy atoms, demonstrating the effectiveness of the chosen
methodology (Supporting Information).
Docking studies of the indolo[3,2-b]quinoline derivatives 3
and 4 were performed with the different topologies of the 21-
mer human telomere G4. The final docking poses showed 3
and 4 interacting with the propeller-like parallel, hybrid-type1
and -type2 models in a stacking mode on the top of the 3’ G-
quartet, while in the anti-parallel basket-type model, the li-
gands behave like groove binders due to the steric hindrance
caused by the TTA loop (Supporting Information). The free
energy of complex formation (DG) was estimated from the
final docking poses after energy refinement (Table 2). The high-
est stabilisers of the human telomere F21T G4 structure, 3d
and 4d, showed to be the most favourable predicted stabilis-
ers, with the lowest DG values, as reported elsewhere for quin-
dolines and fluorenone derivatives.[14c,36] Coefficients of deter-
mination (r2) of 0.74, 0.65, and 0.80 (Supporting Information)
were found between the F21T FRET data and DG for 3 and 4
with the propeller-type parallel, hydrid-type1 and -type2
models, respectively. Analysis of DG values showed the most
stable binding modes converging to the hydrid-type2 human
telomere G4 topology, possibly indicative of the most favoura-
ble conformation in our experimental assays.
Our studies showed that for the propeller-like parallel struc-
ture (1KF1), the N5,N10-indolo[3,2-b]quinolines 3a–c stack at
the centre of the G-quartet. The complex is stabilised by asym-
metrical p–p stacking interactions, and, in some cases, with
the side chains extended over the G-quartet face, stabilised via
a p–cation interaction between protonated terminal nitrogen
and a guanine base. On the other hand, N5,O11 derivatives
4a–c also showed stacking interactions with the guanine
bases of propeller-like parallel G4, but due to a less favourable
conformation, both side chains point toward the outside of
the G4, leading to decreased stabilisation, as shown by higher
DG values (Table 2). In the hybrid-type1 and -type2 topologies,
derivatives 3a–c and 4a–c stack on the edge of the G-quartet
due to steric hindrance caused by the TTA loops. The complex
is also stabilised by asymmetric p–p stacking interactions, and
in some cases the N10 side chain in 3a–c also extends over
the G-quartet, as in the parallel topology, interacting with gua-
nine or thymine bases. The N5 side chains of 3a–c point
toward the outside of the G-quartet core, able to interact with
the TTA loops and/or phosphate backbone and probably justi-
fying the higher stabilisation revealed by the DG values in
comparison with propeller-type parallel topology. On the other
hand, docking results for derivatives 4a–c in the hybrid-type
structures showed both N10 and O11 side chains pointing
toward the outside of the G-quartet core, and probably justify-
ing the highest DG values when compared with 3a–c. General-
ly, unlike in the propeller-type parallel topology, the edge
placement of 3 and 4 found in the hybrid-type structures
allows interactions between the side chains and the TTA loops
and/or backbone, in accord with the higher stabilisation prop-
erties predicted by the DG values (Table 2) in the latest struc-
tures.
As already described, trisubstituted derivatives 3d and 4d
showed higher stabilising properties (DTm and DG) than disub-
stituted derivatives; therefore, the influence of a third aminoal-
kylcarboxylate side chain at position 7 was also modelled.
Compounds 3d and 4d were docked against the four different
G4 topological structures. Docking results in the propeller-like
parallel structure showed derivatives 3d and 4d interacting
with the G-quadruplex structure as already described for 3a–
c and 4a–c, yet with the third side chain at position 7 acting
as a new anchoring point. In both cases, the C7 side chain is
directed outside the G-quartet core, allowing interactions with
the external loops and/or backbone of the G4 structure and
justifying the increased experimental and predicted binding
properties (DTm and DG), when compared with the disubstitut-
ed derivatives. In the hybrid-type G4 structures, 3d and 4d
showed the same asymmetric p–p stacking interactions of the
indolo[3,2-b]quinoline nucleus with two guanine bases, on the
edge of the G-quartet. For instance, Figure 4 shows the top-
ranked docking pose for 4d in the hybrid-type2 human telo-
mere G4 structure.
The complex is stabilised by asymmetric p–p stacking inter-
actions between the indole ring and guanine DG4. Additional-
ly, hydrogen bond interactions between the O11 terminal ni-
trogen and the phosphate backbone, and between the proton-
ated C7 terminal nitrogen and N3 of the guanine DG12 purine
ring improve complex stability. As described for the propeller-
type parallel structure, in the hybrid-type structures, the third
side chain in C7 adds an additional point of contact with G4,
improving the stability of the complex. As such, this additional
binding feature described for 3d and 4d is probably correlated
with the generalised increase in binding predicted by the DG
values, and is in accord with the DTm values found for the tri-
substituted derivatives for all the G4 structures evaluated.
Effect on HCT116 cancer cells
To examine the effect of G4-selective ligands 3d and 4d on
cancer cells, the antiproliferative activity of these compounds
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was evaluated by means of MTS assays with the HCT116 colon
cancer cell line after drug exposure for 96 h. HCT116 cells were
selected, as these cells overexpress Hsp90 and KRas proteins.
We also evaluated the selectivity of 3d and 4d for cancer cells
by assessing the effect of these compounds on the viability of
primary rat hepatocytes. Figure 5 clearly shows that com-
pounds 3d and 4d are ~100-fold more selective for HCT116
cells (IC50=4.50.6 and 5.70.7 mm for 3d and 4d, respec-
tively) than for normal hepatocytes (IC50>100 mm), a pattern
also observed for the standard cytotoxic drug used for colon
cancer treatment, 5-fluorouracil (5-FU).
However, 5-FU shows a distinct anti-proliferative profile rela-
tive to that of G4 ligands 3d and 4d over HCT116 human
colon cancer cells. Although 5-FU seems to be more effective
against HCT116 cancer cells at lower concentrations, its maxi-
mum effect is only of 75% cancer cell growth inhibition, even
at 100 mm, whereas 3d and 4d are more effective, almost com-
pletely inhibiting the growth of HTC116 colon cancer cells at
low-micromolar concentrations (IC90=7.60.9 and 11.0
0.9 mm for 3d and 4d, respectively). The antiproliferative activi-
ties of 3d and 4d compare with those of other disubstituted
indolo[3,2-b]quinolines.[14b] We also found that HCT116 cell line
exposure to 3d and 4d for 72 h decreased the expression
levels of Hsp90 and KRas proteins (Figure 6).
Conclusions
Targeting G4 DNA structures at telomeres and promoter re-
gions of oncogenes may be an effective strategy to control
cancer cell proliferation, but to date, knowledge of the chemi-
cal requirements for both G4 structures and ligands that
Figure 4. Top view of the predicted pose, upon docking with MOE, of com-
pound 4d and the optimised 21-mer hybrid-type2 G4 structure (PDB ID
2JPZ). The G4 structure is represented as a wireframe and the ligand as
sticks. Non-relevant bases and nonpolar hydrogen atoms were removed for
clarity ; grey lines represent p interactions, and black dashed lines indicate
hydrogen bond interactions.
Figure 5. Dose–response curves for a) HCT116 cancer cells and b) primary rat
hepatocytes exposure to 3d, 4d, and 5-fluorouracil (5-FU).
Figure 6. Exposure to compounds 3d and 4d decreases Hsp90 and KRas
protein expression in HCT116 cells. Total proteins were extracted from
HCT116 cells following exposure to 3d, 4d, or vehicle (DMSO) for 72 h and
used to evaluate Hsp90 and KRas steady-state levels by Western blot. Results
are expressed as the mean SEM; *p<0.05 relative to DMSO control.
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would lead to high and selective stabilisation of G4 DNA struc-
tures is still sparse. To further explore and understand the G4-
structure stabilising activity relationship of indolo[3,2-b]quino-
lines, several mono- (2), di- (3a–c, 4a–c), and trialkylamine (3d
and 4d) derivatives were designed, synthesised, and evaluated
for thermal stabilisation of three different G4 DNA sequences
and a hairpin duplex DNA sequence. Further molecular model-
ling studies were performed to better understand the basis of
their binding.
Overall, monosubstituted N5-methyl derivatives, bearing
a full cationic charge at the quinoline nitrogen (N5) atom and
a protonatable amine group at the side chain terminus (com-
pounds 2c–i) are better G4 DNA stabilisers, but seem to be
nonselective for G4 DNA structures. Further analysis of FRET
melting data obtained for indolo[3,2-b]quinolines with one
(2a–m), two (3a–c, 4a–c), or three (3d and 4d) alkylamine
side chains and molecular modelling results for 3a–d and 4a–
d has enabled the following SAR conclusions to be made:
1) Optimal linker length between the distal basic centre and
the indolo[3,2-b]quinoline moiety seems to be that of propyl
linear chains, a pattern also observed with the disubstituted
derivatives (3a–b, 4a–c) and which consistently showed lower
DG values. 2) Aryl substitution at the 11-position has no effect
on G4 thermal stabilisation; compounds 2 j–k show DTm values
similar to that of parent compound 2a. 3) The basicity of side
chains seems to be positively correlated with thermal G4 stabi-
lisation up to pKa ~8.5, consistent with increased concentration
of the protonated species and clearly suggesting that cationic
groups are required for active participation in G4 complex sta-
bilisation. Molecular modelling studies have shown that pro-
tonated side chains extend over G-quartets and can form hy-
drogen bonds and electrostatic interactions with the guanine
bases as well as with TTA loops and phosphate backbones.
4) The introduction of a third side chain, an alkylaminoalkylcar-
boxylate (3d and 4d), increases G4 stabilisation relative to dis-
ubstituted derivatives, leading to selectivity for G4 over duplex
DNA structures and suggests an inter-G4 selectivity trend of
Hsp90A>F21TKRas21R>c-Kit2. 5) The relative position of
side chains plays an important role in the thermal stability of
G4 DNA structures. N5,N10-disubstituted indolo[3,2-b]quino-
lines 3a–c are modest G4 stabilisers, whereas N10,O11-disub-
stituted analogues 4a–c showed very poor G4 DNA stabilising
effects. 6) A chlorine atom at the 3-position of the indolo[3,2-
b]quinoline (compound 3c) is detrimental to G4 DNA complex
stabilisation. Analysis of free binding energies obtained from
molecular modelling studies clearly corroborates the FRET ex-
perimental data. Molecular modelling studies showed that the
relative position of the side chain plays an important role in
complex stabilisation, in which the N5,N10-disubstituted
indolo[3,2-b]quinolines 3a–c can participate in more binding
interactions with the G-quartet face, due to a more favourable
conformation. Additionally, the introduction of a third side
chain at position 7 of the aromatic nucleus (compounds 3d
and 4d) seems to favour the formation of additional hydrogen
bonds and electrostatic interactions with the G-quartet and/or
TTA loops, and as such, increases complex stabilisation.
From all indoloquinoline derivatives studied, the trisubstitut-
ed compounds 3d and 4d, bearing a 7-(aminoalkyl)carboxylate
side chain are the most promising, showing high G4 thermal
stabilisation (DTm between 17 and 8 8C) with an inter-G4 DTm
trend of Hsp90A>KRas21RF21T>c-Kit2, 10-fold selectivity
for G4 over duplex DNA, and 100-fold selectivity for the
HCT116 cancer cell line (IC50 and IC90 <10 mm) over primary rat
hepatocytes. Additionally, 3d and 4d decreased Hsp90 and
KRas expression levels in HCT116 cancer cells. These results are
relevant to the future design and synthesis of new 7-carboxyl-
ate indoloquinoline derivatives that aim to improve both G4
stabilisation and selectivity between various G4s.
Experimental Section
Chemistry
Chemicals were purchased from Sigma–Aldrich Chemical Co. Ltd.
(Spain) and were used without further purification. All compounds
were characterised by NMR spectroscopy, recorded on a Bruker
Avance 400 spectrometer at 400 (1H) and 100 MHz (13C), with sol-
vent as internal reference. Chemical shifts (d) are expressed in
ppm. Signal splitting patterns are described as singlet (s), doublet
(d), triplet (t), quartet (q), quintet (quint) and multiplet (m), or com-
binations thereof. Coupling constants (J) are given in Hz. The
purity of compounds submitted to biological tests was 95% in
all cases as determined from elemental analysis (C, H, N), carried
out by the Elemental Analysis Unit, University of Santiago de Com-
postela (Spain), on a LECO model CHNS-932 elemental analyser.
MS data were recorded using a Micromass Quattro Micro API,
Waters, and were obtained by direct infusion on “Full Scan” mode
(m/z 60–800); sample ionisation was made in positive and negative
electrospray ionisation modes (ESI+ and ESI). Melting points (mp)
were determined with a Bock-Monoscop M instrument. Reactions
were monitored by thin-layer chromatography (TLC) using coated
silica gel plates (Merck, aluminium sheets, silica gel 60 F254) and alu-
minium oxide matrix plates (Sigma–Aldrich, PET support, F254).
Preparative TLC was performed in aluminium oxide 60 F254 (VWR,
200200 mm glass support, F254). Fluorescent-conjugated oligonu-
cleotides were purchased from Eurogentec Ltd. (UK). Fluorescence
measurements were made on a DNA Engine Opticon instrument
(MJ Research).
General procedure A. 2-(2-Bromoacetamido)benzoic acid (6a): A
solution of 2-aminobenzoic acid (10.0 g, 72.9 mmol) in DMF
(30 mL) and 1,4-dioxane (30 mL) was cooled to 0 8C. Bromoacetyl
bromide (8.0 mL, 91.7 mmol, 1.25 equiv) was added dropwise over
a 20 min period, keeping the internal temperature between 0 and
5 8C. After the addition was complete, the ice bath was removed,
and stirring was continued overnight at room temperature. The re-
action mixture was added to H2O (300 mL), and the light-yellow
precipitate which formed was filtered, washed with H2O, until neu-
tral pH, and then dried to give 18.1 g (96%) of 6a as a white solid;
mp: 162–165 8C. 1H NMR (400 MHz, DMSO): d=11.23 (s, NH), 8.06
(d, J=8.4 Hz, 1H), 7.62 (dd, J=7.9, 1.4 Hz, 1H), 7.24 (dd, J=8.4,
7.3 Hz, 1H), 6.82 (dd, J=7.9, 7.3 Hz, 1H), 3.87 ppm (s, 2H); 13C NMR
(100 MHz, DMSO): d=169.20, 165.04, 139.92, 134.06, 131.11,
123.45, 119.99, 117.06, 30.65 ppm.
2-(2-Bromoacetamido)-4-chlorobenzoic acid (6b): Reaction of 2-
amino-4-chlorobenzoic acid (10 g, 58.2 mmol) and bromoacetyl
bromide (14.7 g, 6.3 mL, 72.8 mmol, 1.25 equiv) according to gen-
eral procedure A gave 17.1 g (99%) of 6b as a light-yellow solid;
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mp: 166–168 8C. 1H NMR (400 MHz, DMSO): d=11.73 (s, NH), 8.54
(d, J=2.1 Hz, 1H), 7.98 (d, J=8.6 Hz, 1H), 7.24 (dd, J=8.6, 2.1 Hz,
1H), 4.28 ppm (s, 2H); 13C NMR (100 MHz, DMSO): d=169.03,
165.92, 141.54, 138.95, 133.26, 123.73, 119.61, 115.91, 30.98 ppm.
General procedure B. Synthesis of 2-[2-(phenylamino)acetami-
do]benzoic acid (7a): A solution of 6a (15.0 g, 58.1 mmol) and ani-
line (19.0 mL, 208.3 mmol, 3.5 equiv) in DMF (30 mL) was heated at
120 8C for 18 h. After cooling, the reaction mixture was poured into
ice-water (500 mL), aqueous 5% KOH was added to solubilise the
solid product and adjust the solution to pH 10. Then the mixture
was washed with CH2Cl2 (3200 mL). The combined CH2Cl2 ex-
tracts were set aside, and the aqueous layer was acidified to pH 3
with 5% HBr. The precipitate which formed was collected, washed
with H2O, and then dried, yielding 11.0 g (70%) of 7a as a white
solid; mp: 194–197 8C. 1H NMR (400 MHz, DMSO): d=11.96 (s, NH),
8.61 (d, J=8.7 Hz, 1H), 7.83 (d, J=7.9 Hz, 1H), 7.47 (dd, J=8.7,
8.0 Hz, 1H), 7.02 (dd, J=8.0, 7.9 Hz, 1H), 6.98 (d, J=7.3 Hz, 2H),
6.50 (d, J=7.7 Hz, 1H), 6.48 (dd, J=7.7, 7.3 Hz, 2H), 6.39 (s, NH),
3.73 ppm (s, 2H); 13C NMR (100 MHz, CD3OD): d=170.82, 169.01,
148.08, 140.52, 134.03, 131.08, 128.92, 122.60, 119.32, 116.98,
116.12, 112.36, 48.89 ppm.
4-Chloro-2-{2-[(4-methylphenyl)amino]acetamido}benzoic acid
(7b): A solution of 6b (4.0 g, 13.6 mmol) and 4-methylaniline
(2.93 g, 27.3 mmol, 2 equiv) in DMF (15 mL) was heated at 120 8C
for 48 h and treated according to general procedure B to give
3.68 g (83%) of 7b as a light-yellow solid; mp: 187–189 8C. 1H NMR
(400 MHz, DMSO): d=12.13 (s, 1H), 8.83 (d, J=2.0 Hz, 1H), 7.94 (d,
J=8.5 Hz, 1H), 7.21 (dd, J=8.5, 2.0 Hz, 1H), 6.91 (d, J=8.3 Hz, 2H),
6.49 (d, J=8.3 Hz, 2H), 3.81 (s, 2H), 2.14 ppm (s, 3H); 13C NMR
(100 MHz, DMSO): d=172.15, 168.74, 146.19, 142.00, 139.02,
133.32, 129.88, 126.05, 123.04, 119.14, 115.14, 112.96, 49.67,
20.53 ppm.
2-{2-[(4-(Trifluoromethyl)phenyl)amino]acetamide}benzoic acid
(7c): A solution of 6a (3.0 g, 11.6 mmol) and 4-trifluoromethylani-
line (2.34 g, 1.82 mL, 14.5 mmol, 1.25 equiv) in CH3CN (50 mL) was
held at reflux for 18 h. After this period the solution was cooled in
an ice bath to precipitate. The solid was collected by filtration,
washed with ice-CH3CN and dried to give 2.07 g (53%) of 7c as
a white solid; mp: 218–221 8C. 1H NMR (400 MHz, DMSO): d=11.94
(s, 1H), 8.70 (d, J=8.4 Hz, 1H), 7.94 (dd, J=7.9, 1.5 Hz, 1H), 7.61
(dd, J=7.9, 7.7 Hz, 1H), 7.43 (d, J=8.6 Hz, 2H), 7.42 (s, 1H) 7.15
(dd, J=7.7, 7.4 Hz, 1H), 6.73 (d, J=8.6 Hz, 2H), 3.95 ppm (s, 2H);
13C NMR (100 MHz, DMSO): d=170.39, 169.68, 151.61, 140.92,
134.70, 131.61, 126.81, 123.29, 119.86, 116.38, 112.41, 48.53 ppm;
19F NMR (376 MHz, DMSO): d=59.09 ppm (s).
2-{2-[(4-(Nitro)phenyl)amino]acetamide}benzoic acid (7d): A solu-
tion of 6a (3.0 g, 11.6 mmol) and 4-nitroaniline (3.21 g, 23.2 mmol,
2 equiv) in DMF (30 mL) was held at reflux for 66 h according to
general procedure B to give 2.22 g (60%) of 7d as a yellow solid;
mp: 231–235 8C. 1H NMR (400 MHz, DMSO): d=11.81 (s, 1H), 8.66
(d, J=8.1 Hz, 1H), 8.04 (d, J=9.3 Hz, 2H), 7.95 (dd, J=8.0, 1.5 Hz,
1H), 7.61 (dd, J=9.3, 7.7 Hz, 1H), 7.16 (dd, J=8.1, 7.7 Hz, 1H), 6.74
(d, J=9.3 Hz, 2H), 4.10 ppm (s, 2H); 13C NMR (100 MHz, DMSO):
d=169.79, 169.37, 154.54, 140.85, 137.47, 134.73, 131.63, 126.55,
123.42, 119.98, 116.52, 112.07, 48.06 ppm.
2-{2-[(4-(Ethoxycarbonyl)phenyl)amino]acetamide}benzoic acid
(7e): A solution of 6a (5.0 g, 19.4 mmol) and ethyl 4-aminoben-
zoate (9.6 g, 58.1 mmol, 3.5 equiv) in DMF (30 mL) was held at
reflux for 96 h according to general procedure B to give 2.70 g
(40%) of 7e as a light-yellow solid; mp: >330 8C. 1H NMR
(400 MHz, MeOD): d=8.69 (d, J=8.4, 1H), 8.03 (dd, J=7.9, 1.5,
1H), 7.82 (d, J=8.8, 2H), 7.56 (t, J=7.1, 1H), 7.14 (t, J=7.2, 1H),
6.68 (d, J=8.8, 2H), 4.28 (q, J=7.1, 2H), 4.02 (s, 2H), 1.35 ppm (t,
J=7.1, 3H); 13C NMR (100 MHz, MeOD): d=170.93, 169.12, 167.27,
152.16, 140.22, 133.66, 131.10, 130.93, 122.84, 119.83, 118.64,
116.41, 111.50, 60.04, 48.45, 13.30 ppm.
General procedure C: 5H-indolo[3,2-b]quinolin-11(10H)-one (8a):
A mixture 7a (6.0 g, 21.5 mmol) and polyphosphoric acid (PPA,
160 g) was heated with mechanical stirring at 130 8C for 2 h. The
reaction mixture was added to ice-water (500 mL), neutralised with
saturated KOH solution, and then extracted with EtOAc (3
500 mL). The extract was washed with H2O, dried with brine and
anhydrous Na2SO4, and then the solvent was removed at reduced
pressure. The product was recrystallised from EtOAc with Et2O/
hexane (9:1) to give 3.47 g (67%) of 8a as a light-green solid; mp:
>300 8C. 1H NMR (400 MHz, DMSO): d=12.81 (s, 1H), 11.69 (s, 1H),
8.35 (d, J=8.0 Hz, 1H), 8.28 (d, J=8.0 Hz, 1H), 7.81 (d, J=8.4 Hz,
1H), 7.68 (dd, J=8.4, 7.5 Hz, 1H), 7.50 (d, J=8.2, 1H), 7.49 (dd, J=
8.2, 7.4 Hz, 1H), 7.28 (dd, J=8.0, 7.5 Hz, 1H), 7.20 ppm (dd, J=8.0,
7.4 Hz, 1H); 13C NMR (100 MHz, DMSO): d=167.77, 139.54, 139.05,
130.99, 129.44, 127.84, 125.57, 123.48, 123.24, 121.63, 120.87,
119.25, 118.28, 116.38, 112.98 ppm.
3-Chloro-7-methyl-5H-indolo[3,2-b]quinolin-11(10H)-one (8b):
Reaction of 7b (1.5 g, 4.7 mmol) with PPA (45 g) according to gen-
eral procedure C gave 0.697 g (52%) of 8b, as a light-green solid;
mp: >300 8C. 1H NMR (400 MHz, DMSO): d=12.53 (s, NH), 11.67 (s,
NH), 8.33 (d, J=8.7 Hz, 1H), 7.92 (s, 1H), 7.72 (d, J=1.7 Hz, 1H),
7.42 (d, J=8.5 Hz, 1H), 7.32 (d, J=8.5 Hz, 1H), 7.28 (dd, J=8.7,
1.7 Hz, 1H), 2.47 ppm (s, 3H); 13C NMR (100 MHz, DMSO): d=
167.23, 139.98, 137.57, 135.55, 129.89, 129.05, 128.31, 127.92,
123.86, 121.88, 121.19, 120.33, 117.07, 116.24, 112.95, 21.61 ppm.
11-Oxo-10,11-dihydro-5H-indolo[3,2-b]quinoline-7-carboxylic
acid (8c): Reaction of 7c (2.0 g, 6.1 mmol) with PPA (60 g) accord-
ing to general procedure C gave 0.312 g (19%) of 8c as a light-
brown solid. Reaction of 7e (2.0 g, 5.8 mmol) with PPA (60 g) ac-
cording to general procedure C gave 1.01 g (62%) of 8c as a light-
brown solid; mp: >300 8C. 1H NMR (400 MHz, DMSO): d=12.64 (s,
1H), 12.10 (s, 1H), 8.99 (s, 1H), 8.36 (d, J=7.9 Hz, 1H), 8.04 (dd, J=
8.7, 1.6 Hz, 1H), 7.72 (m, 2H), 7.56 (d, J=8.7 Hz, 1H), 7.32 ppm (dd,
J=7.9, 7.1 Hz, 2H); 13C NMR (100 MHz, DMSO): d=168.18, 167.92,
141.01, 139.60, 131.44, 130.07, 128.55, 125.64, 124.60, 124.20,
123.54, 121.80, 121.29, 118.37, 116.18, 112.77 ppm; MS ESI+ (m/z)
calcd for C16H10N2O3: 278.06, found: 278.96.
2-Hydroxy-3-((4-nitrophenyl)amino)quinolin-4(1H)-one (7 id):
Compound 7d (2.0 g, 6.34 mmol) was reacted in PPA (60 g) for 2 h
at 130 8C according with general procedure C to give a yellow solid
(0.701 g), to yield 7 id at 37%; mp: 225–229 8C. 1H NMR (400 MHz,
DMSO): d=12.86 (s, 1H), 10.54 (s, 1H), 8.70 (d, J=8.4 Hz, 1H), 8.07
(dd, J=7.9, 1.5 Hz, 1H), 7.68 (dd, J=7.9, 7.7 Hz, 1H), 7.52 (d, J=
8.8 Hz, 2H), 7.25 (dd, J=8.4, 7.7 Hz, 1H), 6.56 ppm (d, J=8.8 Hz,
2H); 13C NMR (100 MHz, DMSO): d=169.40, 159.29, 157.46, 146.41,
139.76, 134.46, 131.93, 126.93, 124.23, 122.35, 119.90, 118.25,
114.06 ppm; MS ESI+ (m/z) calcd for C15H11N3O4: 297.07, found:
298.10.
General procedure D. 5,10-Bis(2-(pyrrolidin-1-yl)ethyl)-5H-
indolo[3,2-b]quinolin-11(10H)-one (3a) and 11-(2-(pyrrolidin-1-
yl)ethoxy)-10-(2-(pyrrolidin-1-yl)ethyl)-10H-indolo[3,2-b]quino-
lone (4a): A solution of 8a (70 mg, 0.29 mmol), K2CO3 (619.8 mg,
4.35 mmol, 15 equiv), in dried acetone (20 mL) and 1-(2-chloroe-
thyl)pyrrolidine hydrochloride (203.4 mg, 1.20 mmol, 4 equiv) was
held at reflux overnight. After this period, the solvent was removed
at reduced pressure, and the remaining solid suspended in H2O
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(30 mL). The aqueous solution was extracted with CH2Cl2 (3
30 mL), and the combined organic extracts were washed with H2O,
dried with brine and anhydrous Na2SO4, and decreased to small
volume. The crude mixture was purified by preparative TLC using
CH2Cl2/MeOH (9:1) as eluent to afford compounds 3a (27.3 mg,
21%) and 4a (45.5 mg, 35%). The compounds were recrystallised
as hydrochloride salts with HCl in Et2O after NMR characterisation
and obtained as light-yellow solids. 3a : mp: 227–230 8C; 1H NMR
(400 MHz, CDCl3): d=8.68 (d, J=7.8 Hz, 1H), 8.24 (d, J=8.4 Hz,
1H), 7.72 (m, 2H), 7.69 (d, J=8.5 Hz, 1H), 7.57 (dd, J=8.5, 7.2 Hz,
1H), 7.37 (ddd, J=7.8 Hz, 1H), 7.28 (dd, J=8.4, 7.2 Hz, 1H), 5.13 (t,
J=7.7 Hz, 2H), 4.89 (t, J=7.8 Hz, 2H), 3.11 (m, 4H), 2.85 (m, 4H),
2.78 (m, 4H), 1.92 (m, 4H), 1.89 ppm (m, 4H); 13C NMR (100 MHz,
CDCl3): d=169.05, 139.61, 139.51, 131.62, 130.81, 127.70, 126.78,
124.88, 122.50, 122.46, 121.18, 119.95, 115.10, 114.11, 110.65, 55.82,
54.75, 54.24, 53.44, 47.20, 43.21, 23.62, 23.58 ppm; Anal. calcd for
C27H32N4O·2HCl·2H2O: C 60.33, H 7.13, N 10.42, found: C 60.76, H
7.53, N 10.32. 4a : mp: 212–216 8C; 1H NMR (400 MHz, CDCl3): d=
8.44 (d, J=7.6 Hz, 1H), 8.22 (d, J=8.0 Hz, 1H), 8.20 (d, J=8.0 Hz,
1H), 7.62–7.54 (m, 2H), 7.49 (d, J=8.0 Hz, 1H), 7.48 (dd, J=8.0,
8.0 Hz, 1H) 7.25 (ddd, 1H), 4.79 (t, J=7.5 Hz, 2H), 4.30 (t, J=5.8 Hz,
2H), 3.03 (t, J=5.8 Hz, 2H), 2.86 (t, J=7.5 Hz, 2H), 2.63 (m, 8H),
1.79 (m, 4H), 1.75 ppm (m, 4H); 13C NMR (100 MHz, CDCl3): d=
148.59, 145.92, 144.58, 144.43, 129.95, 129.37, 126.78, 124.88,
124.62, 122.41, 122.14, 122.09, 121.10, 120.13, 109.24, 74.64, 55.81,
54.76, 54.41, 43.43, 23.60, 23.56 ppm; Anal. calcd for
C27H32N4O·2HCl·3H2O: C 58.37, H 7.26, N 10.09, found: C 58.79, H
7.74, N 9.72.
5,10-Bis(3-(piperidin-1-yl)propyl)-5H-indolo[3,2-b]quinolin-
11(10H)-one (3b) and 11-(3-(piperidin-1-yl)propoxy)-10-(3-(piper-
idin-1-yl)propyl)-10H-indolo[3,2-b]quinoline (4b): A solution of
8a (70 mg, 0.29 mmol), K2CO3 (619.8 mg, 4.35 mmol, 15 equiv), in
dried acetone (20 mL) and 1-(3-chloropropyl)piperidine hydrochlo-
ride (237.0 mg, 1.20 mmol, 4 equiv) was reacted and purified ac-
cording to general procedure D to give 3b (45.2 mg, 31%) and 4b
(56.3 mg, 38%) as light-yellow solids. 3b : mp: 258–261 8C; 1H NMR
(400 MHz, CDCl3): d=8.68 (d, J=8.1 Hz, 1H), 8.24 (d, J=8.3 Hz,
1H), 7.80 (d, J=8.6 Hz, 1H), 7.68 (dd, J=8.6, 7.3 Hz, 1H), 7.65 (d,
J=8.4 Hz, 1H), 7.52 (dd, J=8.4, 7.4 Hz, 1H), 7.34 (dd, J=8.1,
7.3 Hz, 1H), 7.22 (dd, J=8.3, 7.4 Hz, 1H), 4.96 (t, J=7.1 Hz, 2H),
4.81 (t, J=7.2 Hz, 2H), 2.53 (t, J=6.3 Hz, 2H), 2.47 (m, 4H), 2.35 (m,
6H), 2.18 (m, 2H), 2.12 (quint, J=7.1 Hz, 2H), 1.69 (quint, J=
5.5 Hz, 4H), 1.58 (quint, J=5.6 Hz, 4H), 1.51 (m, 2H), 1.42 ppm (m,
2H); 13C NMR (100 MHz, CDCl3): d=169.03, 139.79, 139.53, 131.21,
130.66, 127.05, 126.73, 124.91, 122.73, 122.70, 120.84, 119.33,
115.08, 114.37, 110.91, 55.97, 55.91, 55.07, 54.54, 54.46, 53.83,
46.25, 42.78, 28.19, 26.20, 25.98, 24.48 ppm; Anal. calcd for
C31H40N4O·2HCl·5H2O: C 57.49, H 8.09, N 8.65, found: C 57.45, H
8.04, N 8.43. 4b : mp: 241–245 8C; 1H NMR (400 MHz, CDCl3): d=
8.53 (d, J=7.7 Hz, 1H), 8.32 (d, J=7.9 Hz, 1H), 8.31 (d, J=7.8 Hz,
1H), 7.66–7.58 (m, 2H), 7.53 (dd, J=8.4, 7.8 Hz, 1H), 7.51 (d, J=
7.8 Hz, 1H), 7.30 (dd, J=7.7, 7.2 Hz, 1H), 4.57 (t, J=6.9 Hz, 2H),
4.22 (t, J=6.2 Hz, 2H), 2.65 (t, J=7.2 Hz, 2H), 2.47 (m, 4H), 2.26 (m,
6H), 2.20 (quint, J= , 6.2 Hz, 2H), 2.02 (quint, J=6.9 Hz, 2H), 1.64
(quint, J=5.6 Hz, 4H), 1.54 (quint, J=5.6 Hz, 4H), 1.49 (m, 2H),
1.40 ppm (m, 2H); 13C NMR (100 MHz, CDCl3): d=148.58, 145.76,
144.82, 144.53, 129.54, 129.29, 126.55, 124.74, 124.59, 122.34,
122.18, 121.92, 121.25, 119.68, 109.36, 74.13, 56.12, 55.35, 54.68,
54.53, 42.75, 27.58, 26.91, 26.09, 25.97, 24.52, 24.45 ppm; Anal.
calcd for C31H40N4O·3HCl·3.5H2O: C 56.36, H 8.01, N 8.55, found: C
56.66, H 7.67, N 8.53.
3-Chloro-5,10-bis(2-(diethylamino)ethyl)-7-methyl-5H-indolo[3,2-
b]quinolin-11(10H)-one (3c) and 2-((3-chloro-10-(2-(diethylami-
no)ethyl)-7-methyl-10H-indolo[3,2-b]quinolin-11-yl)oxy)-N,N-di-
ethylethanamine (4c): A solution of 8b (80 mg, 0.28 mmol), K2CO3
(580 mg, 4.20 mmol, 15 equiv), in dried acetone (20 mL) and 2-
chloro-N1,N1-diethylethanaminium chloride (192.7 mg, 1.12 mmol,
4 equiv) was reacted and purified according to general proced-
ure D to give 3c (26.3 mg, 19%) and 4c (47.2 mg, 35%) as light-
yellow solids. 3c : mp: 220–222 8C; 1H NMR (400 MHz, CDCl3): d=
8.36 (d, J=8.7 Hz, 1H), 7.77 (s, 1H), 7.48 (d, J=1.6 Hz, 1H), 7.28 (d,
J=8.6 Hz, 1H), 7.17 (d, J=8.6 Hz, 1H), 7.05 (dd, J=8.7, 1.67 Hz,
1H), 4.74 (t, J=7.2 Hz, 2H), 4.54 (t, J=7.2 Hz, 2H), 2.81 (t, J=
7.2 Hz, 2H), 2.68 (t, J=7.2 Hz, 2H), 2.51 (q, J=7.1 Hz, 4H), 2.48 (q,
J=7.1 Hz, 4H), 2.32 (s, 3H), 0.90 (t, J=7.1 Hz, 6H), 0.85 ppm (t, J=
7.1 Hz, 6H); 13C NMR (100 MHz, CDCl3): d=168.55, 140.29, 138.29,
137.60, 130.23, 129.42, 129.11, 128.44, 123.17, 122.96, 121.77,
121.51, 115.10, 114.16, 110.45, 53.13, 50.86, 47.77, 47.57, 43.06,
21.62, 12.05, 11.97 ppm; Anal. calcd for C28H37N4O·2HCl·3.5H2O: C
54.50, H 7.51, N 9.08, found: C 54.60, H 7.57, N 9.31. 4c : mp: 254–
256 8C; 1H NMR (400 MHz, CDCl3): d=8.27 (d, J=9.0 Hz, 1H), 8.20
(s, 1H), 8.19 (d, J=2.1 Hz, 1H), 7.40–7.36 (m, 2H)„ 7.29 (d, J=
8.4 Hz, 1H), 4.54 (t, J=7.6 Hz, 2H), 4.16 (t, J=6.1 Hz, 2H), 2.94 (t,
J=6.1 Hz, 2H), 2.66 (t, J=7.6 Hz, 2H), 2.58 (q, J=7.1 Hz, 4H), 2.50
(q, J=7.1 Hz, 4H), 2.47 (s, 3H), 1.01 (t, J=7.1 Hz, 6H), 0.88 ppm (t,
J=7.1 Hz, 6H); 13C NMR (100 MHz, CDCl3): d=149.39, 145.91,
144.55, 143.27, 132.18, 131.37, 129.57, 127.97, 125.41, 125.21,
122.84, 122.32, 121.98, 120.65, 109.02, 74.82, 53.04, 51.71, 47.71,
47.63, 43.60, 21.16, 12.11, 11.91 ppm; Anal. calcd for
C28H37N4O·2HCl: C 60.70, H 7.10, N 10.11, found: C 60.48, H 6.97, N
9.87.
2-(Diethylamino)ethyl 5,10-bis(2-(diethylamino)ethyl)-11-oxo-
10,11-dihydro-5H-indolo[3,2-b]quinoline-7-carboxylate (3d) and
2-(diethylamino)ethyl 11-(2-(diethylamino)ethoxy)-10-(2-(diethy-
lamino)ethyl)-10H-indolo[3,2-b]quinoline-7-carboxylate (4d): A
solution of 8c (70 mg, 0.23 mmol), K2CO3 (476 mg, 3.45 mmol,
15 equiv), in dried acetone (20 mL) and 2-chloro-N1,N1-diethyletha-
naminium chloride (159.3 mg, 0.92 mmol, 4 equiv) was reacted and
purified according to general procedure D to give 3d (36.2 mg,
31%) and 4d (39.6 mg, 34%) as light-yellow solids. 3d : mp: 175–
178 8C; 1H NMR (400 MHz, CDCl3): d=9.00 (s, 1H), 8.65 (d, J=
8.0 Hz, 1H), 8.19 (d, J=8.9 Hz, 1H), 7.72 (m, 2H), 7.60 (d, J=8.9 Hz,
1H), 7.35 (m, 1H), 5.00 (t, J=6.9 Hz, 2H), 4.87 (t, J=6.7 Hz, 2H),
4.46 (t, J=6.5 Hz, 2H), 3.03 (t, J=6.7 Hz, 2H), 2.94 (t, J=6.9 Hz,
2H), 2.91 (t, J=6.5 Hz, 2H), 2.74 (q, J=7.1 Hz, 4H), 2.68 (m, 8H),
1.10 (m, 12H), 1.04 ppm (t, J=7.2 Hz, 6H); 13C NMR (100 MHz,
CDCl3): d=169.05, 166.79, 141.65, 139.69, 131.74, 131.34, 128.08,
126.75, 125.84, 125.09, 123.16, 121.55, 121.43, 114.88, 114.43,
110.37, 63.18, 53.12, 51.16, 50.81, 47.79, 47.60, 47.49, 47.30, 43.36,
12.01, 11.89, 11.78 ppm; Anal. calcd for C34H49N5O3·3HCl·3.5H2O: C
54.58, H 7.95, N 9.36, found: C 54.67, H 8.01, N 9.27. 4d : mp: 168–
172 8C; 1H NMR (400 MHz, CDCl3): d=9.24 (d, J=1.5 Hz, 1H), 8.39
(dd, J=8.4, 0.9 Hz, 1H), 8.35 (dd, J=8.6, 1.7 Hz, 1H), 8.33 (d, J=
7.5 Hz, 1H), 7.71 (ddd, J=8.4, 6.7, 1.4 Hz, 1H), 7.59 (ddd, J=8.4,
6.8, 1.4 Hz, 1H), 7.52 (d, J=8.7 Hz, 1H), 4.73 (t, J=6.8 Hz, 2H), 4.49
(t, J=6.6 Hz, 2H), 4.31 (t, J=6.2 Hz, 2H), 3.08 (t, J=6.2 Hz, 2H),
2.96 (t, J=6.6 Hz, 2H), 2.83 t, J=6.8 Hz, 2H), 2.70 (q, J=7.2 Hz,
8H), 2.57 (q, J=7.1 Hz, 4H), 1.13 (t, J=7.2 Hz, 6H), 1.11 (t, J=
7.2 Hz, 6H), 0.93 ppm (t, J=7.1 Hz, 6H); 13C NMR (100 MHz, CDCl3):
d=166.84, 148.13, 147.36, 146.30, 145.15, 131.15, 129.46, 127.18,
125.30, 125.08, 124.39, 122.36, 122.16, 121.84, 121.40, 108.95,
74.79, 62.86, 52.97, 51.96, 51.12, 47.77, 47.65, 47.56, 43.88, 12.02,
11.90, 11.83 ppm; Anal. calcd for C34H49N5O3·3HCl·2H2O: C 56.62, H
7.83, N 9.71, found: C 56.44, H 7.99, N 9.73.
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FRET melting assays
The ability of indolo[3,2-b]quinolines to stabilise G-quadruplex
DNA sequences was investigated by using a fluorescence reso-
nance energy transfer (FRET) assay. The labelled oligonucleotides
(Eurogentec Ltd. , UK) contained the donor fluorophore 6-carboxy-
fluorescein (FAM) and the acceptor fluorophore 6-carboxytetrame-
thylrhodamine (TAMRA). Sequences were as follows: F21T (5’-
[FAM]-GGG TTA GGG TAG GGT TAG GG-[TAMRA]-3’), KRas21R (5’-
[FAM]-AGG GCG GTG TGG GAA GAG GGA-[TAMRA]-3’), Hsp90A (5’-
[FAM]-GGG CCA AAG GGA AGG GGT GGG-[TAMRA]-3’), Hsp90C (5’-
[FAM]-AGG GCG GGC CAA AGG GAA GGG GTG GGC-[TAMRA]-3’), c-
Kit1 (5’-[FAM]-AGA GGG AGG GCG CTG GGA GGA GGG GCT-
[TAMRA]-3’), c-Kit2 (5’-[FAM]-CCC GGG CGG GCG CGA GGG AGG
GGA GG-[TAMRA]-3’), HIF-1a (5’-[FAM]-GCG CGG GAG GGG AGA
GGG GGC GGG AGC GCG-[TAMRA]-3’), T-loop (5’-[FAM]-TAT AGC
TAT ATT TTT TTA TAG CTA TA-[TAMRA]-3’). Each oligonucleotide was
initially diluted to 100 mm in nuclease-free water (not DEPC-treat-
ed), purchased from Ambion Applied Biosystems (UK). Stock solu-
tions of 20 mm and subsequent dilutions were obtained in FRET
buffer (60 mm KCl, potassium cacodylate, pH 7.4). The FRET probe
sequences were diluted from stock to the correct concentration
(0.4 mm) and then annealed by heating at 85 8C for 10 min, fol-
lowed by slow cooling to room temperature in the heating block.
Test compounds were prepared as 10 mm DMSO stock solutions
and diluted to 1 mm using 1 mm HCl in HPLC-grade water. The
rest of the dilutions were performed using FRET buffer. Annealed
DNA (50 mL) and test compound solution (50 mL) were distributed
across 96-well RT-PCR plates (BioRad; MJ Research, Waltham, MA,
USA). Relevant controls were also performed to check for interfer-
ence with the assay. Fluorescence readings were made with excita-
tion at l 450–495 nm and detection at l 515–545 nm, taken at in-
tervals of 0.5 8C in the range 30–100 8C, with a constant tempera-
ture being maintained for 30 s prior to each reading to ensure
a stable value. The melting of the F21T G-quadruplex (0.2 mm) was
also monitored in a competition assay in the presence of 0.4, 2.0,
10, and 25 mm non-fluorescent double-stranded competitor 26ds
DNA (5’-CAA TCG GAT CGA ATT CGA TCC GAT TG-3’) at a ligand
concentration of 1 mm. Experiments were performed in triplicate.
Final analysis of the data was carried out with GraphPad Prism
v.5.0 (GraphPad Software Inc. , La Jolla, CA, USA). The advanced
curve-fitting function in GraphPad Prism was used for calculation
of DTm values and associated standard deviations.
Molecular modelling studies
Molecular dynamics : G4 structures obtained from the RSCB Pro-
tein Data Bank (PDB IDs 1KF1, 143D, 2JPZ) were prepared in the
MOE v.2012.10 software package (Chemical Computing Group)[35]
by removing water molecules, adding the missing hydrogen
atoms, and assigning protonation states with the Protonate 3D ap-
plication tool by using the GB/VI formalism at 300 K, pH 7, and salt
concentration of 0.1m. Addition of the two K+ ions to the G4
structures resolved by NMR were made by using the solvate appli-
cation tool present in MOE v.2012.10 which, when necessary, were
placed manually in the central cavity of the G4 structure. The sys-
tems were then subjected to MD simulations using the GROMACS
simulation package 4.5.5[37] and applying the AMBER03[38] force
field. The G4 structures prepared in MOE were inserted in a cubic
box, with no less than 1 nm between the G4 and the simulation
box edge. The system was solvated and neutralised by adding the
required K+ ions. After energy minimisation of the MD box with
the steepest descent method, a 100 ps NVT equilibration run fol-
lowed at 298 K (spatially restraining the oligonucleotide’s heavy
atoms). Finally, the dynamics of the system was studied by sam-
pling the NpT ensemble (T=298 K, p=1 bar) for 10 ns. In all MD
runs, the particle mesh Ewald (PME) formalism was applied in the
long-range electrostatic interactions. The short-range electrostatic
cutoff was 1.2 nm, and the same was applied for the van der Waals
(vdW) interactions. All bonds were constrained with the Lincs algo-
rithm. Nos–Hoover and Parrinello–Rahman were applied to con-
trol the temperature and isotropic pressure (tT=0.2, tp=5.0 ps,
and b=4.5105 bar1). Energy and pressure corrections for the
vdW cutoff were also applied. The structures obtained at the end
of these production runs were used in the docking studies and
were visually compared with the starting PDB structures by using
the alignment application tool present in MOE.
Docking : The crystal structure of the parallel-stranded F21T quad-
ruplex (PDB ID 3CE5)[12b] was prepared with the MOE v.2012.10 soft-
ware package by removing water and adding the missing hydro-
gen atoms and protonation states with Protonate 3D application
tool, at 300 K, pH 7, salt concentration of 0.1m at the GB/VI electro-
static formalism. The co-crystallised ligand found in PDB 3CE5 was
re-docked with the G4 structure using rigid docking protocol, the
triangle matcher placement, the alpha HB free-energy scoring func-
tion, and retaining 100 poses. Final poses were subjected to a final
refinement in the receptor pocket with the AMBER99 force field, at
an RMS gradient threshold of 0.01 and a second rescoring with
alpha HB free-energy scoring function. The best-scoring values
were selected as final poses. Indolo[3,2-b]quinoline ligand struc-
tures were also constructed in MOE and energy minimised with
the MMFF94x force field at an RMS gradient threshold of 0.05. The
refined parallel, antiparallel basket, and hybrid G4 structures (1KF1,
143D, and 2JPZ, respectively) obtained from the MD simulations
were used in docking with the indolo[3,2-b]quinolone ligands as
described above. The G4–ligand interactions were visualised with
the MOE v.2012.10 ligand interactions application tool.
Viability assays
HCT116 human colon carcinoma cells were grown in McCoy’s 5A
medium supplemented with 10% fetal bovine serum (FBS) and 1%
antibiotic/antimycotic (Invitrogen, Grand Island, NY, USA) and main-
tained at 37 8C in a humidified atmosphere of 5% CO2. Cells were
seeded in 96-well plates at 5000 cells per well. Primary rat hepato-
cytes were isolated from male Sprague–Dawley rats (100–150 g) by
collagenase perfusion as described previously.[39] Cell viability was
determined by trypan blue exclusion and was typically 80–85%.
After isolation, hepatocytes were resuspended in William’s E medi-
um and plated on Primaria 96-well culture plates (BD Biosciences,
San Jose, CA, USA) at 5000 cells per well. The cells were maintained
at 37 8C in a humidified atmosphere of 5% CO2 for 4 h to allow at-
tachment. Plates were then washed with medium to remove dead
cells and incubated in William’s E medium containing 10% heat-in-
activated FBS. Test compounds 3d and 4d, and the positive con-
trol 5-fluorouracil (5-FU, Sigma), a common cytotoxic agent used in
colon cancer treatment,[40] were dissolved in DMSO; 24 h after cell
plating, media was removed and replaced with fresh media con-
taining 1–100 mm test compounds and 5-FU, or vehicle (DMSO)
control. After compound exposure for 96 h, cell viability was evalu-
ated using CellTiter 96 AQueous Non-Radioactive Cell Proliferation
Assay (Promega, Madison, WI, USA), using 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS) as previously described.[41] Cell viability data were
expressed as mean SEM or mean SD from at least three inde-
pendent experiments. IC50 and IC90 values were determined using
GaphPad Prism v.5.00 (GraphPad Software).
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Total protein extraction and immunoblotting
HCT116 cells were seeded in 35 mm plates at 150000 cells per
well. Test compounds 3d and 4d were dissolved in DMSO and
added to the cells 24 h after plating, at IC50, 10, and 20 mm. Vehicle
(DMSO) control was also included. After compound exposure for
72 h, cells were collected and processed for total protein extrac-
tion. Briefly, samples were homogenised in ice-cold 1:1 solution of
buffer A [10 mm Tris·HCl pH 7.6, 5 mm MgCl2, 1.5 mm KOAc, 2 mm
dithiothreitol (DTT), and Halt Protease and Phosphatase inhibitor
cocktail, EDTA-free (#78445, Thermo Scientific)] and buffer 2
(10 mm Tris·HCl pH 7.6, 1% Nonidet-P40, and Halt Protease and
Phosphatase inhibitor cocktail), by vigorous vortexing and incubat-
ed on ice for 30 min. Samples were then sonicated (two cycles of
15 s sonication and 30 s ice incubation, using a compact ultrasonic
device with amplitude adjusted to 80% and pulse to 90%; model
UP100H, Hielscher Ultrasonics GmbH, Teltow (Germany); 100 W, ul-
trasonic frequency: 30 kHz) and centrifuged at 10000 g for 10 min
at 4 8C. The clear supernatants containing the total protein extracts
were transferred to a fresh tube and stored at 80 8C. Protein con-
centrations were determined using the BioRad protein assay kit ac-
cording to the manufacturer’s instructions.[40b,42] Steady-state levels
of Hsp90 and KRas proteins were determined by immunoblot anal-
ysis. Briefly, 25 mg of total protein extracts were separated by 10%
SDS-PAGE. After electrophoretic transfer onto nitrocellulose mem-
branes, immunoblots were incubated with 15% H2O2 for 15 min at
room temperature. After blocking with 5% milk solution, the blots
were incubated overnight at 4 8C with primary mouse monoclonal
antibody reactive to Hsp90 or to KRas (#13119 and #sc-30, respec-
tively; Santa Cruz Biotechnology Inc. , Santa Cruz, CA, USA). Finally,
membranes were incubated with secondary anti-mouse sera conju-
gated with horseradish peroxidase (BioRad) for 3 h at room tem-
perature. The membranes were processed for protein detection
using Super Signal substrate (Pierce, Rockford, IL, USA). b-Actin
(#A-5441, Sigma–Aldrich) was used as a loading control. Protein
levels were expressed as mean SEM from at least three inde-
pendent experiments.
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